Schedule 13G ownership disclosure
LYELL IMMUNOPHARMA INC
Security class unavailable · CUSIP: 55083R104
Event date: Unavailable
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 10,071,482
- Percent of class
- 3.9300%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000932471-24-001105
- Form type
- SC 13G
- Filer
- Lyell Immunopharma, Inc.
- CIK
- CIK 1806952
- Filed
- Nov 12, 2024
- Reporting period
- —
- Description
- Schedule 13G beneficial ownership